RUBICON ADVISORS, LLC

Lobbying for DYNAVAX TECHNOLOGIES · Pharmaceuticals

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $75,000.00 income · posted Jan 18, 2026

Lobbying activity 1

Pharmacy

Prescription User Fee, Biomedical Advance Research and Development Authority (BARDA)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem